These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37718903)

  • 21. P38 mitogen-activated protein kinase inhibitor, FR167653, inhibits parathyroid hormone related protein-induced osteoclastogenesis and bone resorption.
    Tao H; Okamoto M; Nishikawa M; Yoshikawa H; Myoui A
    PLoS One; 2011; 6(8):e23199. PubMed ID: 21886782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p38 Mitogen-activated protein kinase is crucially involved in osteoclast differentiation but not in cytokine production, phagocytosis, or dendritic cell differentiation of bone marrow macrophages.
    Li X; Udagawa N; Takami M; Sato N; Kobayashi Y; Takahashi N
    Endocrinology; 2003 Nov; 144(11):4999-5005. PubMed ID: 12960069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methanol Extract of Croton Pycnanthus Benth. Inhibits Osteoclast Differentiation by Suppressing the MAPK and NF-κB Signaling Pathways.
    Lee J; Kim HH
    J Bone Metab; 2014 Nov; 21(4):269-75. PubMed ID: 25489576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Piperine alleviates osteoclast formation through the p38/c-Fos/NFATc1 signaling axis.
    Deepak V; Kruger MC; Joubert A; Coetzee M
    Biofactors; 2015; 41(6):403-13. PubMed ID: 26627060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monocrotaline Suppresses RANKL-Induced Osteoclastogenesis In Vitro and Prevents LPS-Induced Bone Loss In Vivo.
    Wei CM; Su YJ; Qin X; Ding JX; Liu Q; Song FM; Zong SH; Xu J; Zhou B; Zhao JM
    Cell Physiol Biochem; 2018; 48(2):644-656. PubMed ID: 30025412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rifampin suppresses osteoclastogenesis and titanium particle-induced osteolysis via modulating RANKL signaling pathways.
    Zhu L; Kang H; Guo CA; Fan WS; Wang YM; Deng LF; Yan ZQ
    Biochem Biophys Res Commun; 2017 Feb; 484(1):64-70. PubMed ID: 28108285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diphenylhydantoin inhibits osteoclast differentiation and function through suppression of NFATc1 signaling.
    Koide M; Kinugawa S; Ninomiya T; Mizoguchi T; Yamashita T; Maeda K; Yasuda H; Kobayashi Y; Nakamura H; Takahashi N; Udagawa N
    J Bone Miner Res; 2009 Aug; 24(8):1469-80. PubMed ID: 19292614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo.
    Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T
    Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.
    Hasegawa H; Kido S; Tomomura M; Fujimoto K; Ohi M; Kiyomura M; Kanegae H; Inaba A; Sakagami H; Tomomura A
    J Biol Chem; 2010 Aug; 285(33):25448-57. PubMed ID: 20547767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo.
    Kim JY; Oh HM; Kwak SC; Cheon YH; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2015; 38(1):66-74. PubMed ID: 25744460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A natural compound (LCA) isolated from Litsea cubeba inhibits RANKL-induced osteoclast differentiation by suppressing Akt and MAPK pathways in mouse bone marrow macrophages.
    Yu L; Jia D; Feng K; Sun X; Xu W; Ding L; Xin H; Qin L; Han T
    J Ethnopharmacol; 2020 Jul; 257():112873. PubMed ID: 32298753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
    Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY
    Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
    Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
    BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
    Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
    J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lonafarnib Inhibits Farnesyltransferase via Suppressing ERK Signaling Pathway to Prevent Osteoclastogenesis in Titanium Particle-Induced Osteolysis.
    Huang L; Chen W; Wei L; Su Y; Liang J; Lian H; Wang H; Long F; Yang F; Gao S; Tan Z; Xu J; Zhao J; Liu Q
    Front Pharmacol; 2022; 13():848152. PubMed ID: 35300293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pregnenolone Inhibits Osteoclast Differentiation and Protects Against Lipopolysaccharide-Induced Inflammatory Bone Destruction and Ovariectomy-Induced Bone Loss.
    Sun X; Zhang C; Guo H; Chen J; Tao Y; Wang F; Lin X; Liu Q; Su L; Qin A
    Front Pharmacol; 2020; 11():360. PubMed ID: 32292342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metformin attenuates osteoclast-mediated abnormal subchondral bone remodeling and alleviates osteoarthritis via AMPK/NF-κB/ERK signaling pathway.
    Guo H; Ding D; Wang L; Yan J; Ma L; Jin Q
    PLoS One; 2021; 16(12):e0261127. PubMed ID: 34914744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway.
    Huh JE; Lee WI; Kang JW; Nam D; Choi DY; Park DS; Lee SH; Lee JD
    J Nat Prod; 2014 Nov; 77(11):2423-31. PubMed ID: 25397676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.